Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
46,752,465
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
7,927,898
-
Shares change
-
-457,611
-
Total reported value, excl. options
-
$42,334,234
-
Value change
-
-$3,223,883
-
Put/Call ratio
-
4.4%
-
Number of buys
-
34
-
Number of sells
-
-17
-
Price
-
$5.34
Significant Holders of Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) as of Q3 2024
76 filings reported holding OTLK - Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share as of Q3 2024.
Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7,927,898 shares
of 46,752,465 outstanding shares and own 17% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (1,559,560 shares), GREAT POINT PARTNERS LLC (1,293,028 shares), BlackRock, Inc. (1,044,988 shares), VANGUARD GROUP INC (855,876 shares), Altium Capital Management LP (541,549 shares), SPHERA FUNDS MANAGEMENT LTD. (413,545 shares), GEODE CAPITAL MANAGEMENT, LLC (341,959 shares), Caligan Partners LP (318,699 shares), Schonfeld Strategic Advisors LLC (285,714 shares), and STATE STREET CORP (232,542 shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.